Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This study evaluated the efficacy and safety of three doses of botulinum toxin A (BTX-A; Dysport) in 125 patients (mean age 5.2 years, SD 2; 54% male)with dynamic equinus spasticity during walking. Participants were randomized to receive Dysport (10, 20, or 30 units/kg) or placebo to the gastrocnemius muscle of both legs. Muscle length was calculated from electrogoniometric measurements and the change in the dynamic component of gastrocnemius shortening at four weeks was prospectively identified as the primary outcome measure. All treatment groups showed statistically significant decreases in dynamic component compared with placebo at 4 weeks. Mean improvement in dynamic component was most pronounced in the 20 units/kg group, being equivalent to an increase in dorsiflexion with the knee extended at 19 degrees, and was still present at 16 weeks. The safety profile of the toxin appears satisfactory.

Original publication

DOI

10.1017/s0012162201002730

Type

Journal article

Journal

Developmental medicine and child neurology

Publication Date

10/2002

Volume

44

Pages

666 - 675

Addresses

Musgrave Park Hospital, Belfast, Northern Ireland. bakerr@cryptic.rch.unimelb.edu.au

Keywords

Muscle, Skeletal, Humans, Muscle Spasticity, Cerebral Palsy, Neurologic Examination, Treatment Outcome, Walking, Injections, Intramuscular, Double-Blind Method, Dose-Response Relationship, Drug, Child, Child, Preschool, Female, Male, Botulinum Toxins, Type A